Rhelion Life Sciences Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRUFF research report →
Price Chart
About the company
Based in Toronto, Ontario, Red Light Holland Corp. is primarily involved in the cultivation, production, and retail of recreational magic truffles for the Dutch market. Beyond its own cultivated offerings, the company also engages in the sourcing, distribution, and international export of various truffle varieties.
- CEO
- Todd Michael Shapiro
- IPO
- 2021
- Employees
- 104
- HQ
- Toronto, ON, CA
Get TickerSpark's AI analysis on TRUFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.60M
- P/E
- -2.07
- PEG
- 0.05
- P/S
- 3.00
- P/B
- 1.07
- EV/EBITDA
- -1.32
- Div Yield
- 0.00%
- Gross Margin
- 31.66%
- Op Margin
- -105.56%
- Net Margin
- -145.45%
- ROE
- -41.33%
- ROIC
- -33.45%
Latest fiscal year · YoY change
- Revenue
- $4.20M-15.1%
- Gross Profit
- $1.59M-16.8%
- Op Income
- $-4,124,766
- Net Income
- $-6,101,998-51.0%
- EPS
- $-0.01-44.6%
- OCF Growth
- -63.3%
- FCF Growth
- -27.2%
- 52W High
- $0.04
- 52W Low
- $0.01
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 0.96
- RSI (14)
- 48
- Avg Volume
- 124.81K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Red Light Holland said revenue rose, gross margins stayed healthy, and the company is pivoting toward retail, fresh mushrooms, and cautious growth in emerging psychedelic markets.· March 1, 2024
- Quarter revenue was $1.3 million, up 9.9% year over year; nine-month revenue was $3.5 million, up 28.9%.
- Gross profit margins remained strong at 42.3% for the quarter and 43.6% year to date, though management said mix and pricing pressured margins a bit.
- Management said the business is shifting away from DTC/Amazon toward B2B and retail channels, where it sees better economics and more control.
- Happy Caps distribution increased, but there were questions about Amazon reviews, sold-out SKUs, and product labeling/instructions.
- The Peterborough farm build remains a major future catalyst, with management saying it is still on track and could support much higher revenue once ramped.
For the quarter ended December 31, revenue was $1.3 million, up 9.9% from the same period last year. For the nine months ended December 31, revenue was $3.5 million, up 28.9% year over year. Gross profit margin was 42.3% for the quarter and 43.6% on a year-to-date basis. Management did not provide EPS in the call. On guidance, the company said Amazon is a slower season and that all SKUs should be back in the coming weeks, but it is shifting emphasis toward retail/B2B channels. On the farm build, management reiterated prior expectations that the project could ultimately support about 80,000 per week and roughly $16 million to $17 million in revenue, with ramp-up stages along the way.
Todd Shapiro struck an upbeat but defensive tone, repeatedly emphasizing transparency, shareholder engagement, and cautious long-term growth. Strategically, he said the company is building around brand development, distribution gains, and a shift toward business-to-business and retail rather than relying mainly on direct-to-consumer sales. He also said Red Light wants to avoid the mistakes of cannabis companies that overbuilt too early, preferring to wait for the right market and regulatory conditions before moving aggressively into psychedelics.
David Ascott focused on the hard numbers and framed the quarter as evidence that revenue growth is outpacing overhead growth. He cited $1.3 million in quarterly revenue, $3.5 million in nine-month revenue, and gross margins of 42.3% and 43.6%, saying the company is maintaining healthy profitability on gross profit despite seasonality and product-mix swings. He said the growth in revenue and gross margin has outpaced G&A movement and that the company is working to right-size costs across North America and Europe.
The most notable questions centered on the drop in gross profit despite higher revenue, Amazon reviews and alleged mislabeled Happy Caps boxes, retailer listings that may no longer be active, the strategy for SR Wholesale, the Peterborough farm build, and possible share buybacks. Management said the gross margin softness mainly reflected product mix, seasonality, and some pricing pressure from competitive conditions, especially in Happy Caps and Amazon. On the farm, management said the build is being timed carefully to save money, with orders and construction staged over time, and on buybacks Todd said approximately 1.5 million shares have already been repurchased under the normal course issuer bid and that future repurchases will depend on cash and the quarterly budget.
The bullish case from this call is that revenue is growing, gross margins are still solid, and management believes it is improving the cost structure while scaling. The company also described meaningful distribution gains in Happy Caps, progress toward larger retail contracts, a potentially important Peterborough farm catalyst, and optionality in psilocybin and related adjacent markets.
The bear case is that gross margin softness, Amazon friction, and consumer-review complaints suggest scaling pains and weaker economics in parts of the business. Management also acknowledged a burn, a difficult economy, long sales cycles, and regulatory uncertainty around emerging psychedelic markets, while the stock-price discussion and defensive Q&A tone highlighted ongoing investor concerns.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.7%
- Shares Outstanding
- 614.12M
- Float Shares
- 575.17M
Our TRUFF coverage
Recent articles, reports, and earnings notes.
No research on TRUFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRUFF report →Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Issued New United States Patent, Extending the Broadest Natural Psilocybin Patent Estate
newsfilecorp.com · Nov 19
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to UCSF for Phase 1 Trial of Psilocybin in Healthy Older Adults with Low Well-Being
newsfilecorp.com · Nov 17
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to King's College London
newsfilecorp.com · Nov 9
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Ships PEX010 to the University of Southern California for the Expanded Mindfulness Assisted Psychedelic Therapy Trial
newsfilecorp.com · Nov 3
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing
newsfilecorp.com · Nov 2
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder
newsfilecorp.com · Oct 28
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression
newsfilecorp.com · Oct 16
Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor
newsfilecorp.com · Oct 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.